A decade of immune-checkpoint inhibitors in cancer therapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update

Magoola, M., & Niazi, S. K. (2025) · Cancers · doi:10.3390/cancers17111882 · Cited by 58

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy

Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., & Shen, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040520 · Cited by 50

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs

Tatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. S., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01379-y · Cited by 52

Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis

Fitzsimmons, T. S., Singh, N., Walker, T. D. J., Newton, C. L., Evans, D. G., Crosbie, E. J., & Ryan, N. A. J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1192762 · Cited by 48

Microglia and macrophages in glioblastoma: landscapes and treatment directions

Solomou, G., Young, A. M. H., & Bulstrode, H. J. C. J. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13657 · Cited by 54

CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer

Tarannum, M., Dinh, K., Vergara, J. A., Birch, G. C., Abdulhamid, Y. Z., Kaplan, I. E., Ay, O., Maia, A., Beaver, O., Sheffer, M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn0881 · Cited by 48

PD-L1 siRNA–hyaluronic acid conjugate for dual-targeted cancer immunotherapy

Kim, S., Heo, R., Song, S. H., Song, K., Shin, J. M., Oh, S. J., Lee, H., Chung, J. E., Park, J. H., & Kim, T. W. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.023 · Cited by 48

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression

Nelson, A., Gebremeskel, S., Lichty, B. D., & Johnston, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003923 · Cited by 47

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer

Simão, D. C., Zarrabi, K. K., Mendes, J. L., da Luz, R., Garcia, J. A., Kelly, W. K., & Barata, P. C. (2023) · Cancers · doi:10.3390/cancers15051412 · Cited by 47

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

Ma, Y., Xue, J., Zhao, Y., Zhang, Y., Huang, Y., Yang, Y., Fang, W., Guo, Y., Li, Q., Ge, X., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006654 · Cited by 47

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma

Carroll, T. M., Chadwick, J. A., Owen, R. P., White, M. J., Kaplinsky, J., Peneva, I., Frangou, A., Xie, P. F., Chang, J., Roth, A. J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.006 · Cited by 50

Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database

Frey, C., & Etminan, M. (2024) · Antibodies · doi:10.3390/antib13030059 · Cited by 48

Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma

Sehgal, K., Παππά, Θ., Shin, K., Schiantarelli, J., Liu, M., Ricker, C. A., Besson, N. R., Jones, S. M., Welsh, E. L., Pfaff, K. L., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4019 · Cited by 48

Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

Heras‐Murillo, I., Mañanes, D., Munné, P., Núñez, V., Herrera, J., Català-Montoro, M., Álvarez, M., del Pozo, M. Á., Melero, I., Wculek, S. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58289-1 · Cited by 60

The Role and Potential of 18F-FDG PET/CT in Malignant Melanoma: Prognostication, Monitoring Response to Targeted and Immunotherapy, and Radiomics

Filippi, L., Bianconi, F., Schillaci, O., Spanu, A., & Palumbo, B. (2022) · Diagnostics · doi:10.3390/diagnostics12040929 · Cited by 44

Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity

Mansouri, S., Heylmann, D., Stiewe, T., Kracht, M., & Savai, R. (2022) · eLife · doi:10.7554/elife.79895 · Cited by 45

Patient-Centered Care in the Management of Cancer During Pregnancy

Sorouri, K., Loren, A. W., Amant, F. C., & Partridge, A. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100037 · Cited by 53

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1

Miao, B., Hu, Z., Mezzadra, R., Hoeijmakers, L. L., Fauster, A., Du, S., Yang, Z., Sator‐Schmitt, M., Engel, H., Li, X., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.008 · Cited by 48

Optimal delivery of RNA interference by viral vectors for cancer therapy

Wong, B., Birtch, R., Rezaei, R., Jamieson, T. R., Crupi, M. J. F., Diallo, J., & Ilkow, C. S. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.012 · Cited by 47

Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment

Li, Y., Wang, L., Ma, W., Wu, J., Wu, Q., & Sun, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06744-4 · Cited by 49

The fellowship of regulatory and tissue-resident memory cells

Barros, L., Ferreira, C., & Veldhoen, M. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00456-w · Cited by 47

Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study

Moretto, R., Rossini, D., Catteau, A., Antoniotti, C., Giordano, M., Boccaccino, A., Ugolini, C., Proietti, A., Conca, V., Kassambara, A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006633 · Cited by 46

Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors

Liu, B., Zhu, X., Kong, L., Wang, M., Spanoudis, C. M., Chaturvedi, P., George, V., Jiao, J., You, L., Egan, J. O., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.001 · Cited by 42

Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management

Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424872 · Cited by 49

Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies

Dziadek, S., Kraxner, A., Cheng, W., Yang, T.-H. O., Flores, M., Theiss, N., Tsao, T., Andersson, E. K., Harring, S. V., Bröske, A.-M. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352615 · Cited by 44

Emerging trends and therapeutic applications of monoclonal antibodies

Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 45

Boosting the synergism between cancer ferroptosis and immunotherapy via targeted stimuli-responsive liposomes

Gao, Z., Zhang, J. J., Hou, Y., Lu, J., Liang, J., Gao, Y., Li, B., Gao, S., Zhao, Y., Gao, S., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122442 · Cited by 44

Immune checkpoint inhibitor–associated nephritis—treatment standard

Barbir, E.-B., Kitchlu, A., & Herrmann, S. M. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae184 · Cited by 52

Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity

Du, J., Chen, H., You, J., Hu, W., Liu, J., Qiao, L., Zhang, Y., Gao, J., Lin, M., Foster, C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.004 · Cited by 50

Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment

Sun, B. L. (2021) · The Prostate · doi:10.1002/pros.24213 · Cited by 43

Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling

Lim, W.-J., Lee, M., Oh, Y., Fang, X.-Q., Lee, S., Lim, C.-H., Park, J., & Lim, J.-H. (2021) · Cells · doi:10.3390/cells10092488 · Cited by 45

Cysteinyl Leukotriene Pathway and Cancer

Tsai, M., Chang, W., Chuang, C., Wu, K., Cheng, C.-H., Sheu, C., Hsu, Y., & Hung, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010120 · Cited by 43

Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry

Nowatzke, J. F., Guedeney, P., Palaskas, N., Lehmann, L., Éderhy, S., Zhu, H., Cautela, J., Francis, S. A., Courand, P., Deswal, A. M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.018 · Cited by 41

Maintenance therapy in acute myeloid leukemia: advances and controversies

Senapati, J., Kadia, T. M., & Ravandi, F. (2023) · Haematologica · doi:10.3324/haematol.2022.281810 · Cited by 42

Microphysiological systems for solid tumor immunotherapy: opportunities and challenges

Abizanda-Campo, S., Virumbrales-Muñoz, M., Humayun, M., Mármol, I., Beebe, D. J., Ochoa, I., Oliván, S., & Ayuso, J. M. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-023-00616-x · Cited by 42

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Middha, P., Thummalapalli, R., Betti, M. J., Yao, L., Quandt, Z., Balaratnam, K., Bejan, C. A., Cardenas, E. R., Falcon, C. J., Faleck, D. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44512-4 · Cited by 42

Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms

Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45

Challenges and Opportunities in the Clinical Translation of High-Resolution Spatial Transcriptomics

Pentimalli, T. M., Karaiskos, N., & Rajewsky, N. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023417 · Cited by 45

Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer

Zhang, W., Hwang, J., Yadav, D., An, E., Kwak, M., Lee, P. C.-W., & Jin, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179125 · Cited by 42

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

Maritaz, C., Broutin, S., Chaput, N., Marabelle, A., & Paci, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01182-3 · Cited by 45

Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy

Negură, I., Tanasa, M. P., & Danciu, M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102629 · Cited by 44

A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors

Paun, R. A., Jurchuk, S., & Tabrizian, M. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10601 · Cited by 48

CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1–positive regulator for tumor immune evasion

Wang, S., Iyer, R., Han, X., Wei, J., Li, N., Yang, C. H., Zhou, Y., Gao, Q., Zhang, L., Yan, M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167728 · Cited by 43

Immunotherapy in Sarcoma: Current Data and Promising Strategies

Wood, G. E., Meyer, C. F., Petitprez, F., & D’Angelo, S. P. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432234 · Cited by 47

Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies

Sun, W., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12587 · Cited by 42

Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity

Kumar, M., Thangavel, C., Becker, R. C., & Sadayappan, S. (2020) · Cancers · doi:10.3390/cancers13010086 · Cited by 46

Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy

Kim, J., Choi, Y., Kim, D., Yoon, H. Y., & Kim, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091908 · Cited by 40

The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms

Pollini, T., Adsay, V., Capurso, G., Molin, M. D., Esposito, I., Hruban, R. H., Luchini, C., Maggino, L., Matthaei, H., Marchegiani, G., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00235-7 · Cited by 42

The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment

Bartish, M., Abraham, M. J., Gonçalves, C., Larsson, O. S., Rolny, C., & Rincon, S. V. D. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00567-5 · Cited by 42

Cancer-Associated Fibroblasts: Immunosuppressive Crosstalk with Tumor-Infiltrating Immune Cells and Implications for Therapeutic Resistance

Pawar, J. S., Salam, M. A., Dipto, M. S. U., Al-Amin, M. Y., Salam, M. T., Sengupta, S., Kumari, S., Gujjari, L., & Yadagiri, G. (2025) · Cancers · doi:10.3390/cancers17152484 · Cited by 43

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications

Wanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 40

T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis

Costa-Madeira, J. C., Trindade, G. B., Almeida, P. H. P., Silva, J. S., & Carregaro, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835711 · Cited by 40

Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism

Gao, T. A., & Chen, Y. Y. (2022) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-092120-092914 · Cited by 41

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer

Xu, P., Wasielewski, L. J., Yang, J. C., Cai, D., Evans, C. P., Murphy, W. J., & Liu, C. (2022) · Biomedicines · doi:10.3390/biomedicines10081778 · Cited by 42

The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities

Hinneh, J. A., Gillis, J. L., Moore, N. L. T., Butler, L. M., & Centenera, M. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982231 · Cited by 42

Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response

Zheng, H., Wang, M., Zhang, S., Hu, D., Yang, Q., Chen, M., Zhang, X., Zhang, Y., Dai, J., & Liou, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.80017 · Cited by 38

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers

Strati, A. D., Adamopoulos, C., Kotsantis, I., Psyrri, A. K., Lianidou, E. S., & Papavassiliou, A. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031235 · Cited by 41

Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy

Zhang, B., Wu, J., Jiang, H., & Zhou, M. (2025) · Cells · doi:10.3390/cells14050320 · Cited by 39

Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers

Tata, A., Dodard, G., Fugère, C., Leget, C., Ors, M., Rossi, B., Vivier, É., & Brossay, L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1933808 · Cited by 41

Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept

León‐Triana, O., Pérez‐Martínez, A., Ramírez, M. R., & Pérez‐García, V. M. (2021) · Cancers · doi:10.3390/cancers13040703 · Cited by 38

Engineered in vitro tumor models for cell-based immunotherapy

Ando, Y., Mariano, C. F., & Shen, K. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.076 · Cited by 38

Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: An evidence-based hypothesis

Akbari, H., Taghizadeh‐Hesary, F., & Bahadori, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.12.001 · Cited by 38

Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review

Tao, W., Sun, Q., Xu, B., & Wang, R. (2025) · Life · doi:10.3390/life15020283 · Cited by 39

T-cell Exhaustion in Organ Transplantation

Angeletti, A., Cantarelli, C., Riella, L. V., Fribourg, M., & Cravedi, P. (2021) · Transplantation · doi:10.1097/tp.0000000000003851 · Cited by 39

Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model

Song, C., Kim, N., Nam, R. H., Choi, S. I., Jang, J. Y., Kim, J. W., Na, H. Y., & Lee, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215780 · Cited by 40

Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review

Eskandari-Malayeri, F., & Rezaei, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996145 · Cited by 38

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Swatler, J., Turos-Korgul, L., Kozłowska, E., & Piwocka, K. (2021) · Cancers · doi:10.3390/cancers13061203 · Cited by 38

Nephrotoxicity in cancer treatment: An update

Chen, C., Xie, D., Gewirtz, D. A., & Li, N. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.005 · Cited by 42

The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells

Senent, Y., Tavira, B., Pı́o, R., & Ajona, D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215900 · Cited by 39

Cancer Vaccines in the Immunotherapy Era: Promise and Potential

Verma, C., Pawar, V. A., Srivastava, S., Tyagi, A., Kaushik, G., Shukla, S. K., & Kumar, V. (2023) · Vaccines · doi:10.3390/vaccines11121783 · Cited by 40

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P. R., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00253 · Cited by 37

Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

Ming, Q., Antfolk, D., Price, D. A., Manturova, A., Medina, E., Singh, S., Mason, C. C., Tran, T. H., Smalley, K. S. M., Leung, D. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51930-5 · Cited by 39

Current Progress and Future Directions of Immunotherapy in Head and Neck Squamous Cell Carcinoma

Sim, E. S., Nguyen, H. C. B., Hanna, G. J., & Uppaluri, R. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.5254 · Cited by 39

Emerging glyco‐based strategies to steer immune responses

Anderluh, M., Berti, F., Bzducha‐Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik-Popińska, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., et al. (2021) · FEBS Journal · doi:10.1111/febs.15830 · Cited by 38

Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC)

Sardarabadi, P., Kojabad, A. A., Jafari, D., & Liu, C. (2021) · Biosensors · doi:10.3390/bios11100394 · Cited by 39

Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy

Wan, C., Sun, Y., Hu, Y., Huang, J., Lu, L., Gao, Y., Zi, H., He, Q., Sun, J., Lovell, J. F., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101323 · Cited by 37

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy

Mummareddy, S., Pradhan, S., Narasimhan, A. K., & Natarajan, A. (2021) · Biosensors · doi:10.3390/bios11120500 · Cited by 37

MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma

Jiang, K., Zhang, Q., Fan, Y., Li, J., Zhang, J., Wang, W., Fan, J., Guo, Y., Liu, S., Hao, D., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00923-8 · Cited by 38

Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies

Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 37

T cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response

Hickey, J. W., Haist, M., Horowitz, N. B., Caraccio, C., Tan, Y., Rech, A. J., Baertsch, M., Rovira‐Clavé, X., Zhu, B., Vazquez, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113494 · Cited by 39

Integrating integrins with the hallmarks of cancer

Haake, S. M., Rios, B. L., Pozzi, A., & Zent, R. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.04.003 · Cited by 39

ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration

Zhang, C., Li, K., Zhu, H., Cheng, M., Chen, S., Ling, R., Wang, C., & Chen, D. (2024) · Nature Communications · doi:10.1038/s41467-024-51096-0 · Cited by 39

Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives

Shahzadi, M., Rafique, H., Waheed, A., Naz, H., Waheed, A., Zokirova, F. R., & Khan, H. (2024) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355241305856 · Cited by 44

Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma

Mou, W., Deng, Z., Zhu, L., Jiang, A., Lin, A., Xu, L., Deng, G., Huang, H., Guo, Z., Zhu, B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1727 · Cited by 36

Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices

Gupta, B., & Kim, J. O. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00527-x · Cited by 37

Near infrared photoimmunotherapy of cancer; possible clinical applications

Wakiyama, H., Kato, T., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2021) · Nanophotonics · doi:10.1515/nanoph-2021-0119 · Cited by 38

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy

Maiorano, B. A., Lorusso, D., Maiorano, M. F. P., Ciardiello, D., Parrella, P., Petracca, A., Cormio, G., & Maiello, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073871 · Cited by 39

miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma

Pathania, A. S., Prathipati, P., Olwenyi, O. A., Chava, S. P., Smith, O. V., Gupta, S. C., Chaturvedi, N. K., Byrareddy, S. N., Coulter, D. W., & Challagundla, K. B. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.010 · Cited by 36

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art

Feola, T., Carbonara, F., Verrico, M., Crescenzo, R. M. D., Gianno, F., Colonnese, C., Arcella, A., Alcubierre, D. D., Tomao, F., Esposito, V., et al. (2022) · Cancers · doi:10.3390/cancers14174093 · Cited by 36

Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies

Zahavi, D. J., & Hodge, J. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108871 · Cited by 38

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions

Tong, Y., Fan, X., Liu, H., & Liang, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495675 · Cited by 36

Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling

Nikolić, I., Cursons, J., Shields, B., Chappaz, S., Sudholz, H., Meng, X., Constantinescu, P., Vijayakumaran, R., D’Angelo, M. E., Foroutan, M., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.011 · Cited by 39

Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance

Traba, J., Sack, M. N., Waldmann, T. A., & Antón, O. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657293 · Cited by 39

Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients

van Wigcheren, G. F., de Haas, N., Mulder, T. A., Horrevorts, S. K., Bloemendal, M., Bree, S. H.-D., Mao, Y., Kiessling, R. W., van Herpen, C. M. L., Flórez‐Grau, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1935557 · Cited by 35

HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct

Evans, A. M., Salnikov, M. Y., Gameiro, S. F., Vareki, S. M., & Mymryk, J. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164825 · Cited by 37

Lentigo maligna (melanoma): A systematic review and meta‐analysis on surgical techniques and presurgical mapping by reflectance confocal microscopy

Elshot, Y. S., Tio, D., With, A., Ouwerkerk, W., Zupan‐Kajcovski, B., Crijns, M. B., Limpens, J., Klop, W. M. C., Bekkenk, M. W., Balm, A. J. M., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18880 · Cited by 35

Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma

Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39

Learning from the nexus of autoimmunity and cancer

Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33

Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

Quinaglia, T., Gongora, C. A., Awadalla, M., Hassan, M. Z. O., Zafar, A., Drobni, Z. D., Mahmood, S., Zhang, L., Coelho‐Filho, O. R., Suero‐Abreu, G. A., et al. (2022) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2022.06.014 · Cited by 34

Immune Cell Migration to Cancer

Ryan, A. T., Kim, M., & Lim, K. (2024) · Cells · doi:10.3390/cells13100844 · Cited by 35

["Immune checkpoint inhibitors in oncology"].

Daëron, M., & Vivier, É. (2021) · PubMed

Meditating on Cancer Management at the Time of Immunotherapy

Lopci, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113025

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Weidhaas, J. B. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.030

Immunotherapy for cancer

Lee, A. J. X. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.007 · Cited by 3

Immuno-oncology: A changing paradigm in cancer therapy

Abdel-Rahman, O. M. (2016) · Advances in Modern Oncology Research · doi:10.18282/amor.v2.i6.187 · Cited by 1